Miwa Miyoshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Miwa Miyoshi has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Akihiro Sunaga
Osaka University Graduate School of Medicine
3 shared publications - Daisaku Nakatani
Osaka University Graduate School of Medicine
3 shared publications - Koichi Inoue
Cardiovascular Division National Hospital Organization Osaka National Hospital Osaka Japan
3 shared publications - Masaharu Masuda
Cardiovascular Center Kansai Rosai Hospital Amagasaki Japan
3 shared publications - Masato Okada
Cardiovascular Center, Sakurabashi Watanabe Advanced Healthcare Hospital Osaka Japan
3 shared publications Nobuhiko Makino
3 shared publications
Latest Publications
- 21 September 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 49 (11) , 1744-1747
How Should an Embolized Atrial Leadless Pacemaker Be Retrieved From the Pulmonary Artery?
- 21 September 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 49 (11) , 1744-1747
How Should an Embolized Atrial Leadless Pacemaker Be Retrieved From the Pulmonary Artery?
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (6) , e013612
Impact of Initial Extensive Ablation on Left Atrial Gaps During Redo Procedures and Subsequent Outcomes in Persistent Atrial Fibrillation
BACKGROUND: The efficacy of extensive linear ablation strategies, in addition to pulmonary vein (PV) isolation, remains controversial in persistent atrial fibrillation (AF) ablation. Gaps in previously ablated lesions can induce arrhythmias and potentially decrease the effectiveness of extensive ablation. This study evaluated the incidence of conduction gaps, gap-related reentry, and subsequent recurrence following redo AF ablation in the EARNEST-PVI trial (Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation; REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03514693 ). METHODS: The EARNEST-PVI trial is a randomized controlled study evaluating index ablation strategies for persistent AF. Of the 512 trial participants, 115 who underwent redo AF ablation (pulmonary vein isolation [PVI]-alone redo [n=69] and PVI-plus linear redo [n=46]) were included in the present study. Left atrial conduction gaps, the occurrence of left atrial tachycardias during redo procedures, and subsequent recurrences were compared between the PVI-alone redo group and the PVI-plus linear ablation redo group. RESULTS: In the PVI-alone redo group, electrical PV gaps were observed in 38 (57%) patients. In the PVI-plus redo group, 19 (41%) had PV gaps, 10 (22%) had gaps in left atrial linear lines, and 11 (24%) had gaps in both. During the redo session, 19 left atrial tachycardias were observed or induced in 15 patients. Atrial tachycardias were more frequently observed in the PVI-plus group than in the PVI-alone group (23.9% versus 5.8%; P =0.005). The occurrence of left atrial tachycardias was associated with gaps in linear lesions, whereas PV gaps alone were associated with subsequent recurrence after redo (hazard ratio, 0.54 [95% CI, 0.31–0.95]; P =0.033). CONCLUSIONS: In the redo AF ablation of the EARNEST-PVI trial, left atrial conduction gaps were more frequent in patients who underwent extensive linear ablation during the index procedure. While all gaps during redo were potentially arrhythmogenic, PV gaps alone were associated with recurrence after redo AF ablation. REGISTRATION: URL: https://www.umin.ac.jp/ctr/index-j.htm ; Unique identifier: UMIN000019449.
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (6) , e013612
Impact of Initial Extensive Ablation on Left Atrial Gaps During Redo Procedures and Subsequent Outcomes in Persistent Atrial Fibrillation
BACKGROUND: The efficacy of extensive linear ablation strategies, in addition to pulmonary vein (PV) isolation, remains controversial in persistent atrial fibrillation (AF) ablation. Gaps in previously ablated lesions can induce arrhythmias and potentially decrease the effectiveness of extensive ablation. This study evaluated the incidence of conduction gaps, gap-related reentry, and subsequent recurrence following redo AF ablation in the EARNEST-PVI trial (Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation; REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03514693 ). METHODS: The EARNEST-PVI trial is a randomized controlled study evaluating index ablation strategies for persistent AF. Of the 512 trial participants, 115 who underwent redo AF ablation (pulmonary vein isolation [PVI]-alone redo [n=69] and PVI-plus linear redo [n=46]) were included in the present study. Left atrial conduction gaps, the occurrence of left atrial tachycardias during redo procedures, and subsequent recurrences were compared between the PVI-alone redo group and the PVI-plus linear ablation redo group. RESULTS: In the PVI-alone redo group, electrical PV gaps were observed in 38 (57%) patients. In the PVI-plus redo group, 19 (41%) had PV gaps, 10 (22%) had gaps in left atrial linear lines, and 11 (24%) had gaps in both. During the redo session, 19 left atrial tachycardias were observed or induced in 15 patients. Atrial tachycardias were more frequently observed in the PVI-plus group than in the PVI-alone group (23.9% versus 5.8%; P =0.005). The occurrence of left atrial tachycardias was associated with gaps in linear lesions, whereas PV gaps alone were associated with subsequent recurrence after redo (hazard ratio, 0.54 [95% CI, 0.31–0.95]; P =0.033). CONCLUSIONS: In the redo AF ablation of the EARNEST-PVI trial, left atrial conduction gaps were more frequent in patients who underwent extensive linear ablation during the index procedure. While all gaps during redo were potentially arrhythmogenic, PV gaps alone were associated with recurrence after redo AF ablation. REGISTRATION: URL: https://www.umin.ac.jp/ctr/index-j.htm ; Unique identifier: UMIN000019449.
- Open Access
- 5 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (17) , e029651
Long‐Term Impact of Additional Ablation After Pulmonary Vein Isolation: Results From EARNEST‐PVI Trial
Background: An optimal strategy for left atrial ablation in addition to pulmonary vein isolation (PVI) in patients with persistent atrial fibrillation (AF) has not been determined. Methods and Results: We conducted an extended follow‐up of the multicenter randomized controlled EARNEST‐PVI (Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation) trial, which compared 12‐month rhythm outcomes in patients with persistent AF between patients randomized to a PVI‐alone strategy (n=248) or PVI‐plus strategy (n=248; PVI followed by left atrial additional ablation, including linear ablation or ablation targeting areas with complex fractionated electrograms). The present study extended the follow‐up period to 3 years after enrollment. Outcomes were compared not only between randomly allocated groups but also between on‐treatment groups categorized by actually created ablation lesions. Recurrence rate of AF or atrial tachycardia (AT) was lower in the randomly allocated to PVI‐plus group than the PVI‐alone group (29.0% versus 37.5%, P =0.036). On‐treatment analysis revealed that patients with PVI+linear ablation (n=205) demonstrated a lower AF/AT recurrence rate than those with PVI only (26.3% versus 37.8%, P =0.007). In contrast, patients with PVI+complex fractionated electrograms ablation (n=37) had an AF/AT recurrence rate comparable to that of patients with PVI only (40.5% versus 37.8%, P =0.76). At second ablation in 126 patients with AF/AT recurrence, ATs excluding common atrial flutter were more frequent in patients with PVI+linear ablation than in those with PVI only (32.6% versus 5.7%, P <0.0001). Conclusions: Left atrial ablation in addition to PVI was efficacious during 3‐year follow‐up. Linear ablation was superior to other ablation strategies but may increase iatrogenic ATs. Registration: URL: http://www.umin.ac.jp/ctr/index‐j.htm ; Unique identifier: UMIN000019449.
- 5 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (17) , e029651
Open AccessLong‐Term Impact of Additional Ablation After Pulmonary Vein Isolation: Results From EARNEST‐PVI Trial
Background: An optimal strategy for left atrial ablation in addition to pulmonary vein isolation (PVI) in patients with persistent atrial fibrillation (AF) has not been determined. Methods and Results: We conducted an extended follow‐up of the multicenter randomized controlled EARNEST‐PVI (Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation) trial, which compared 12‐month rhythm outcomes in patients with persistent AF between patients randomized to a PVI‐alone strategy (n=248) or PVI‐plus strategy (n=248; PVI followed by left atrial additional ablation, including linear ablation or ablation targeting areas with complex fractionated electrograms). The present study extended the follow‐up period to 3 years after enrollment. Outcomes were compared not only between randomly allocated groups but also between on‐treatment groups categorized by actually created ablation lesions. Recurrence rate of AF or atrial tachycardia (AT) was lower in the randomly allocated to PVI‐plus group than the PVI‐alone group (29.0% versus 37.5%, P =0.036). On‐treatment analysis revealed that patients with PVI+linear ablation (n=205) demonstrated a lower AF/AT recurrence rate than those with PVI only (26.3% versus 37.8%, P =0.007). In contrast, patients with PVI+complex fractionated electrograms ablation (n=37) had an AF/AT recurrence rate comparable to that of patients with PVI only (40.5% versus 37.8%, P =0.76). At second ablation in 126 patients with AF/AT recurrence, ATs excluding common atrial flutter were more frequent in patients with PVI+linear ablation than in those with PVI only (32.6% versus 5.7%, P <0.0001). Conclusions: Left atrial ablation in addition to PVI was efficacious during 3‐year follow‐up. Linear ablation was superior to other ablation strategies but may increase iatrogenic ATs. Registration: URL: http://www.umin.ac.jp/ctr/index‐j.htm ; Unique identifier: UMIN000019449.
- Open Access
- 16 December 2022
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2022 (12) , omac130
Subcutaneous-implantable cardioverter defibrillator lead dislodgement in a juvenile catecholamine-induced polymorphic ventricular tachycardia patient
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a relatively rare inherited arrhythmic disease that causes sudden cardiac death, and is caused by mutations in the cardiac ryanodine receptor (RyR2) or sarcoplasmic reticulum protein calsequestrin 2 gene (CASQ2). A 16-year-old man was diagnosed with CPVT and was implanted with a Subcutaneous-implantable Cardioverter Defibrillator (S-ICD), but defibrillation electrode detachment occurred early after placement. We suspected that a two-incision technique was the possible cause. We also report on changes in surface ECG in remote monitoring of the device. TAKE HOME MESSAGE Although two-incision techniques are becoming the mainstream method of S-ICD implantation, we should consider that the three-incision technique may be advantageous in highly active patients. Remote monitoring may also be useful for early detection of S-ICD dislodgement.
- 16 December 2022
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2022 (12) , omac130
Open AccessSubcutaneous-implantable cardioverter defibrillator lead dislodgement in a juvenile catecholamine-induced polymorphic ventricular tachycardia patient
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a relatively rare inherited arrhythmic disease that causes sudden cardiac death, and is caused by mutations in the cardiac ryanodine receptor (RyR2) or sarcoplasmic reticulum protein calsequestrin 2 gene (CASQ2). A 16-year-old man was diagnosed with CPVT and was implanted with a Subcutaneous-implantable Cardioverter Defibrillator (S-ICD), but defibrillation electrode detachment occurred early after placement. We suspected that a two-incision technique was the possible cause. We also report on changes in surface ECG in remote monitoring of the device. TAKE HOME MESSAGE Although two-incision techniques are becoming the mainstream method of S-ICD implantation, we should consider that the three-incision technique may be advantageous in highly active patients. Remote monitoring may also be useful for early detection of S-ICD dislodgement.